Bayer Won at the Supreme Court. The $7.25 Billion Offer Stayed.

Some Roundup plaintiffs chose to stay out of Monsanto's settlement. Then Monsanto won at the Supreme Court.

By August, Bayer said the settlement administrator was receiving requests to undo those opt-outs following the ruling. Its subsidiary was still seeking approval of a deal worth up to $7.25 billion. The company had won a major legal argument. It had not abandoned the effort to buy a negotiated end to claims.

That is the turn worth watching when Judge Timothy Boyer holds the fairness hearing in St. Louis on September 14 at 9:30 a.m. Central. The question is no longer simply how much Monsanto offered. It is what the same offer is worth after the alternative becomes harder. Bayer's August 6 statement · Court order and current hearing notice

Getting back in is a second decision

Section 12.3 of the corrected settlement agreement allows a class member to ask to revoke an opt-out before final judgment. But the request becomes effective only with Monsanto's express written consent or a court order. The agreement gives the defendant discretion. Sending a request is not the same as being readmitted.

The exit has its own dispute. Section 12.2 sets requirements for a valid opt-out, provides a route for challenging it, and contemplates a final list attached to the judgment. The document separates someone who wants out, someone whose exit is legally effective, and someone asking to return. The settlement's reach depends on which claims it actually binds.

There is also a defendant termination right in Section 12.5, tied to a confidential exhibit. The public agreement does not disclose the threshold. Corrected settlement agreement, §§12.2–12.5, printed pp. 58–60, under Documents

The lawsuit lost a central argument

John Durnell sued Monsanto after using Roundup for about two decades and developing non-Hodgkin lymphoma. His Missouri case argued that the product's label should have warned about cancer. A jury awarded him more than $1 million on that theory. The Missouri Court of Appeals upheld the result.

On June 25, the Supreme Court reversed and sent the case back. The 7–2 ruling held that federal pesticide law preempted Durnell's state-law failure-to-warn claim. The Environmental Protection Agency had approved the label without a cancer warning; the state-law claim would require Monsanto to add one.

The ruling decides that failure-to-warn theory. The proposed agreement seeks releases through a separate claims program. Winning the legal argument and completing that bargain remain different tasks. Supreme Court opinion, syllabus and opinion pp. 1–2

The number stayed. The alternative changed.

The class settlement was proposed in February, before the Supreme Court ruled. Its class includes people exposed to Roundup products before February 17, 2026 who have not been diagnosed with non-Hodgkin lymphoma, as well as people already diagnosed. Benefits depend on the agreement's eligibility rules and specified diagnosis periods. Final court approval remains pending.

Bayer's August 6 statement said additional time would allow the administrator to process opt-out revocation requests received following Durnell and resolve challenges to opt-outs.

The court's own order is narrower. Boyer cited a significant number of disputes about whether opt-out requests were valid. He gave those disputes more time and moved the hearing to September 14. The order does not measure how many people changed their minds or establish why they did so. Bayer statement · August 6 order, pp. 1–2, on the settlement site

A ruling that weakens a separate lawsuit can make the same settlement more attractive without adding a dollar to the offer. That is our reading of the incentive, not a claim about each person's reason for seeking to return. The public sources establish requests, not a count of successful returns.

$7.25 billion is a ceiling, not Monday's check

The payment provisions explain another part of the bargain. Article IV sets a maximum fund amount of $7.25 billion, subject to specified credits, termination rights and other conditions. It lays out initial funding, scheduled annual payments and a possible additional period for defined unpaid claimants.

The first two annual payments are $550 million each. Later scheduled payments decline. Section 4.3 says those funding obligations and the specified attorneys' fees do not receive interest or inflation adjustments. Those are contract terms, not proof that any scheduled deposit or claimant payment has occurred.

For the company, the proposed agreement offers a different kind of value from an appellate opinion: a defined claims program, releases and bounded funding obligations. For class members, the same structure means eligibility rules, allocation rules and timing matter alongside the headline amount. The document is a compromise over both litigation risk and when money can move. Corrected agreement, Article IV, printed pp. 22–24

What Monday can change

Monday is an approval hearing. It is not a promised payment date, and the hearing's arrival does not tell us whether final approval will be granted or when a ruling will come.

The next useful document is the court's order: what it approves, how it addresses objections and opt-out disputes, and which conditions still stand between approval and an effective settlement. A later appeal could also matter. Treating the date on the calendar as closure would skip the very fight the court has spent more time sorting out.

Monsanto won on the label. Monday's hearing concerns the bargain.